anti-rheumatic agents
Showing 1 - 25 of >10,000
Rheumatic Diseases Trial in Ciudad Autónoma de Buenos Aires (Immunosuppressive Agents)
Completed
- Rheumatic Diseases
- Immunosuppressive Agents
-
Ciudad Autónoma de Buenos Aires, Caba, ArgentinaSociedad Argentina de Reumatología
Jan 30, 2023
Stroke, Medication Adherence Trial in Kumasi (Polycap)
Not yet recruiting
- Stroke
- Medication Adherence
-
Kumasi, GhanaKwame Nkrumah Institute of Science & Technology
Jul 19, 2023
Uncomplicated Plasmodium Falciparum Malaria Trial (INE963, KAE609, SoC (Coartem))
Not yet recruiting
- Uncomplicated Plasmodium Falciparum Malaria
- INE963
- +3 more
- (no location specified)
Feb 17, 2023
Osteomyelitis-associated Pressure Ulcers by Surgical Flaps and
Not yet recruiting
- Disability or Chronic Disease Leading to Disablement
- +2 more
- Surgical flap and anti-bacterial agents
-
Garches, FranceDepartment of Physical Medicine and Rehabilitation, Raymond Poin
Feb 1, 2023
Relapsed/Refractory Non-Hodgkin Lymphoma Trial in Duarte, Amsterdam (BMS-986458, Rituximab)
Not yet recruiting
- Relapsed/Refractory Non-Hodgkin Lymphoma
-
Duarte, California
- +1 more
Oct 13, 2023
Solid Tumor Trial in Chuo-ku (ROSE12, Atezolizumab)
Recruiting
- Solid Tumor
-
Chuo-ku, Tokyo, JapanNational Cancer Center Hospital
Jun 14, 2023
Atherosclerosis, Adherence, Medication, Tolerance Trial in Kumasi (Polycap)
Completed
- Atherosclerosis
- +2 more
-
Kumasi, GhanaKwame Nkrumah University of Science & Technology
Sep 29, 2022
Crohn's Disease, Ulcerative Colitis Trial in Montpellier (Immuno monitoring)
Completed
- Crohn's Disease
- Ulcerative Colitis
- Immuno monitoring
-
Montpellier, FranceUniversity hospital
Dec 13, 2022
IBD, Biological Substance; Adverse Effect Trial in Haifa (Azithromycin Pill, Placebo)
Not yet recruiting
- Inflammatory Bowel Diseases
- Biological Substance; Adverse Effect
- Azithromycin Pill
- Placebo
-
Haifa, IsraelRambam Health Care Campus
Oct 25, 2022
Anti-IL-6 Receptor Monoclonal Antibodies on Treatment of
Recruiting
- Rheumatoid Arthritis
- +3 more
-
Barcelona, SpainHospital de la Santa Creu i Sant Pau
Apr 25, 2022
Mild Cognitive Impairment, Alzheimer Trial in Worldwide (Canakinumab, Placebo)
Recruiting
- Mild Cognitive Impairment
- Alzheimer Disease
- Canakinumab
- Placebo
-
Charlestown, Massachusetts
- +11 more
Nov 11, 2022
Tumors Trial run by the NCI (Nilotinib and Paclitaxel)
Recruiting
- Neoplasms
- Nilotinib and Paclitaxel
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
Myocardial Ischemia, Rheumatic Diseases Trial in Puerto Rico, United States (Caplan IVR)
Active, not recruiting
- Myocardial Ischemia
- Rheumatic Diseases
- Caplan IVR
-
San Francisco, California
- +4 more
Mar 15, 2022
Risk of NSAIDs on Anastomotic Leak for Rectal Surgery
Recruiting
- Anastomotic Leak
- Anti-Inflammatory Agents, Non-Steroidal
-
Chongqing, None Selected, ChinaArmy Medical Center
Nov 24, 2023
Rheumatic Diseases, Mood Disorders Trial in Besançon (Blood sample)
Recruiting
- Rheumatic Diseases
- Mood Disorders
- Blood sample
-
Besançon, FranceUniversity Hospital
Apr 5, 2022
Rheumatoid Arthritis, Rheumatic Diseases Trial in Leiden (Abatacept, Methotrexate)
Completed
- Rheumatoid Arthritis
- Rheumatic Diseases
-
Leiden, NetherlandsLeiden University Medical Center
Aug 16, 2022
COVID-19 in Rheumatic Inflammatory Diseases Under
Active, not recruiting
- Chronic Inflammatory Rheumatism
- Biological samples
-
Montpellier, Occitanie, FranceCentre hopsitalier universitaire de Montpellier
Jun 10, 2022
Treatment Resistant Depression, MDD, Analgesia Trial in Brooklyn (VTS-K)
Recruiting
- Treatment Resistant Depression
- +12 more
-
Brooklyn, New YorkMaimonides Medical Center
Dec 12, 2022
PTSD, Alcohol Use Disorder Trial in Baltimore (Pregabalin plus BBCET, Placebo plus BBCET)
Active, not recruiting
- PTSD
- Alcohol Use Disorder
- Pregabalin plus BBCET
- Placebo plus BBCET
-
Baltimore, MarylandUniversity of Maryland School of Medicine
Mar 25, 2022
Collateral Damage From COVID-19 Pandemic Observed in Patients
Completed
- Age Related Macular Degeneration
- +2 more
- Questionnaire
- Data collection up to 1 year
-
Ecully, France
- +3 more
Mar 2, 2022